Bank of New York Mellon
VIRX

Bank of New York Mellon’s Viracta Therapeutics, Inc. Common Stock VIRX Stock Holding History

Bank of New York Mellon’s Portfolio VIRX Stock Details VIRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q2 		– Sell
-12,681
Closed -$20.2K – 4475
2023
Q1 		$20.2K Hold
12,681
– – ﹤0.01% 4309
2022
Q4 		$18.5K Sell
12,681
-46
-0.4% -$134 ﹤0.01% 4367
2022
Q3 		$54K Hold
12,727
– – ﹤0.01% 4308
2022
Q2 		$49K Sell
12,727
-96,488
-88% -$275K ﹤0.01% 4349
2022
Q1 		$520K Sell
109,215
-798
-0.7% -$2.4K ﹤0.01% 3681
2021
Q4 		$402K Buy
110,013
+2,075
+2% +$11.1K ﹤0.01% 3934
2021
Q3 		$866K Buy
107,938
+9,643
+10% +$95K ﹤0.01% 3473
2021
Q2 		$1.11M Buy
+98,295
New +$986K ﹤0.01% 3340
2019
Q1 		– Sell
-287
Closed -$4K – 4267
2018
Q4 		$4K Hold
287
– – ﹤0.01% 4217
2018
Q3 		$20K Hold
287
– – ﹤0.01% 4210
2018
Q2 		$21K Sell
287
-67
-19% -$5.96K ﹤0.01% 4168
2018
Q1 		$33K Buy
354
+67
+23% +$11.5K ﹤0.01% 4226
2017
Q4 		$37K Buy
+287
New +$26.9K ﹤0.01% 4242
2016
Q3 		– Sell
-287
Closed -$33K – 4323
2016
Q2 		$33K Buy
287
+6
+2% +$665 ﹤0.01% 4234
2016
Q1 		$32K Sell
281
-25
-8% -$3.79K ﹤0.01% 4135
2015
Q4 		$58K Buy
306
+25
+9% +$4.68K ﹤0.01% 4160
2015
Q3 		$48K Hold
281
– – ﹤0.01% 4250
2015
Q2 		$177K Sell
281
-727
-72% -$386K ﹤0.01% 3916
2015
Q1 		$518K Sell
1,008
-3
-0.3% -$1.51K ﹤0.01% 3590
2014
Q4 		$542K Sell
1,011
-602
-37% -$271K ﹤0.01% 3587
2014
Q3 		$2.42M Buy
1,613
+374
+30% +$541K ﹤0.01% 2749
2014
Q2 		$1.7M Buy
1,239
+424
+52% +$492K ﹤0.01% 3002
2014
Q1 		$1.13M Buy
815
+10
+1% +$11.6K ﹤0.01% 3208
2013
Q4 		$801K Sell
805
-4
-0.5% -$4.14K ﹤0.01% 3407
2013
Q3 		$842K Sell
809
-5,462
-87% -$5.84M ﹤0.01% 3329
2013
Q2 		$6.83M Buy
+6,271
New +$6.99M ﹤0.01% 2009

Other funds holding VIRX

BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
LCM
Laurion Capital Management New York $2.29B AUM 75.73% 1-Year Est. Return
SB
Samsara BioCapital Palo Alto, California $1.03B AUM 214.94% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
MCM
MAI Capital Management Independence, Ohio $17.7B AUM 18.87% 1-Year Est. Return
ACM
Aisling Capital Management New York $476M AUM 128.63% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return

Bank of New York Mellon's VIRX Position: Q2 2023 in Review

Bank of New York Mellon sold out of Viracta Therapeutics, Inc. Common Stock (VIRX) in Q2 2023, closing a stake of 12,681 shares — an estimated $20.2K sold.

Bank of New York Mellon first reported a position in VIRX in Q2 2013 and held it in 26 quarters. The position peaked at $6.83M in Q2 2013. 41 funds tracked by Wall St. Rank hold VIRX as of Q2 2023.

  • Bank of New York Mellon reported no remaining Viracta Therapeutics, Inc. Common Stock position as of Q2 2023 after selling out during the quarter.
  • Bank of New York Mellon sold 12,681 Viracta Therapeutics, Inc. Common Stock shares in Q2 2023, an estimated $20.2K.
  • Bank of New York Mellon first reported a position in Viracta Therapeutics, Inc. Common Stock in Q2 2013 and held it in 26 quarters.
  • Bank of New York Mellon's Viracta Therapeutics, Inc. Common Stock position peaked at $6.83M in Q2 2013.
  • 41 funds tracked by Wall St. Rank held Viracta Therapeutics, Inc. Common Stock as of Q2 2023.

Based on Bank of New York Mellon's 13F filing for Q2 2023, filed 3 Aug 2023.